Zevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Zevra Therapeutics

05/08/2026 23:21

Zevra Therapeutics Inc ZVRA.OQ reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.21.  The mean expectation of nine analysts for the quarter was for earnings of 11 cents per share. Wall Street expected results to range from 3 cents to 20 cents per share.
Revenue rose 53.3% to $39.66 million from a year ago; analysts expected $33.88 million. 
Zevra Therapeutics Inc's reported EPS for the quarter was 14 cents​.
The company reported quarterly net income of $8.75 million.
Zevra Therapeutics Inc shares had fallen by 26.6% this quarter and gained 17.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.4% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Zevra Therapeutics Inc is $24.50, about 57.1% above its last closing price of $10.52
This summary was machine generated from LSEG data August 5 at 10:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.11
0.14
Beat
Mar. 31 2026 
0.08
0.18
Beat
Dec. 31 2025 
0.05
0.21
Beat
Sep. 30 2025 
-0.03
-0.01
Beat